Vivos Therapeutics (NASDAQ:VVOS) Announces Earnings Results, Misses Estimates By $0.07 EPS

Vivos Therapeutics (NASDAQ:VVOS) posted its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07), Zacks reports. Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%.

Vivos Therapeutics Stock Performance

Shares of Vivos Therapeutics stock traded up $0.00 during midday trading on Wednesday, hitting $0.59. The company had a trading volume of 265,593 shares, compared to its average volume of 189,360. The company has a fifty day simple moving average of $1.06 and a 200 day simple moving average of $1.65. The stock has a market cap of $8.09 million, a price-to-earnings ratio of -0.29 and a beta of 6.25. The company has a quick ratio of 0.24, a current ratio of 0.24 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a 12-month low of $0.57 and a 12-month high of $7.95.

Wall Street Analyst Weigh In

VVOS has been the subject of several research reports. HC Wainwright lowered their target price on Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating for the company in a report on Friday, April 17th. Ascendiant Capital Markets reduced their price target on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $2.75.

Insider Activity at Vivos Therapeutics

In other news, major shareholder Michael C. Skaff bought 1,353,625 shares of Vivos Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was bought at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the purchase, the insider directly owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

Institutional Trading of Vivos Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new stake in shares of Vivos Therapeutics in the second quarter worth about $65,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Vivos Therapeutics in the second quarter worth about $220,000. DRW Securities LLC boosted its stake in shares of Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares during the last quarter. Finally, Connective Capital Management LLC purchased a new stake in shares of Vivos Therapeutics in the third quarter worth about $620,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.